[Stuttering Research Group Home Page] [Stuttering Group Researchers] [Stuttering: A view from Psychiatry] [Patient Enrollment] [Internet Resources]
Potential Studies
Present Studies
Publications
Abstracts
The genetics of stuttering
fMRI investigation of stuttering
Principal Investigator: Gerald A. Maguire, M.D.
Co-Investigators: David L. Franklin, M.S., Glyndon D. Riley, Ph.D., Michael
Maguire, L.P.T., and Gerald E. Maguire, M.D.
Objective: To determine the efficacy and tolerability of olanzapine in the treatment of stuttering. Other aspects include cognition, social phobia, and theoretical models
Gottschalk LA, Bechtel RJ, Maguire GA, Harrington DE, Levinson DM, Franklin DL, Carcamo D (2000). Computerized measurement of cognitive impairment and associated neuropsychiatric dimensions. Comprehensive Psychiatry Sep-Oct; 41(5):326-33.
Maguire GA, Riley GD, Franklin DL, Gottschalk LA (2000). Risperidone for the treatment of stuttering. Journal of Clinical Psychopharmacology Aug; 20(4):479-82.
Lavid N, Franklin DL, Maguire GA (1999). Management of child and adolescent stuttering with olanzapine: three case reports. Annals of Clinical Psychiatry Dec; 11(4):233-6.
Maguire GA, Gottschalk LA, Riley GD, Franklin DL, Bechtel RJ, Ashurst J (1999). Stuttering: neuropsychiatric features measured by content analysis of speech and the effect of risperidone on stuttering severity. Comprehensive Psychiatry Jul-Aug; 40(4):308-14.
Gottschalk LA (1999). The application of a computerized measurement of the content analysis of natural language to the assessment of the effects of psychoactive drugs. Methods and Findings in Experimental and Clinical Pharmacology Mar; 21(2):133-8.
Riley GD, Wu JC, Maguire GA (1997). PET scan evidence of parallel cerebral systems related to treatment effects. Speech Production: motor control, brain research and fluency disorders. Hulstijn W, Peters HRM, van Lieshout PHHM, eds. International Congress Series 1146, Amsterdam: Excerpta Medica: 321-27.
Wu JC, Riley GD, Maguire GA, Najafi A, Tang C (1997). PET scan evidence of parallel cerebral systems related to treatment effects: FDG and FDOPA pet scan findings. Speech Production: motor control, brain research and fluency disorders. Hulstijn W, Peters HRM, van Lieshout PHHM, eds. International Congress Series 1146, Amsterdam: Excerpta Medica: 329-39.
Maguire GA, Riley GD, Wu JC, Franklin DL, Potkin S (1997). PET scan evidence of parallel cerebral systems related to treatment effects: effects of risperidone in the treatment of stuttering. Speech Production: motor control, brain research and fluency disorders. Hulstijn W, Peters HRM, van Lieshout PHHM, eds. International Congress Series 1146, Amsterdam: Excerpta Medica: 379-82.
Wu JC, Maguire G, Riley G, Lee A, Keator D, Tang C, Fallon J, Najafi A (1997) Increased dopamine activity associated with stuttering. Neuroreport Feb 10; 8(3):767-70.
Wu JC, Maguire G, Riley G, Fallon J, LaCasse L, Chin S, Klein E, Tang C, Cadwell S, Lottenberg S (1995). A positron emission tomography [18F]deoxyglucose study of developmental stuttering. Neuroreport Feb 15; 6(3):501-5.
Gottschalk LA, Bechtel R (1995). Computerized measurement of the content analysis of natural language for use in biomedical and neuropsychiatric research. Computer Methods and Programs in Biomedicine Jul; 47(2):123-30.
Lavid N, Franklin DL, Maguire GA (2000). The Treatment of Adult Stuttering with Olanzapine: An Open Label Prospective Analysis. Presented at the Annual Meeting of the American Psychiatric Association, May 13-18, Chicago, IL.